Loading clinical trials...
Loading clinical trials...
Trauma remains the leading cause of death and disability for Americans age 1-44. Trauma can cause internal bleeding, and this bleeding is often hard to detect without sophisticate tests that take time to complete and analyze. In addition, internal bleeding, including bleeding into the lung and chest cavity, as well as other blood loss, happens in many critically ill patients. For example, for hemorrhage, it is very difficult to detect active hemorrhage and to determine optimal rates of fluid and blood resuscitation. Diffuse optical spectroscopy has the potential to accurately assess adequacy of tissue perfusion, oxygenation, tissue oxygen extraction, and cytochrome oxidation states that may be critical to optimal treatment, end- organ preservation, and survival.
The research' want to monitor tissue perfusion and indicators of tissue damage and viability in critically ill patients by using DOS. Non-invasive Optical Techniques DOS,near-infrared diffuse optical spectroscopy (NIR-DOS. NIR-DOS provides functional physiologic tissue/organ information without ionizing radiation and without withdrawing any blood, in a cost-effective and rapid manner. The application of frequency-domain photon migration analysis (FDPM) to NIRS allows independent measurements of tissue absorption and scattering properties at depths of 1 cm or more below the skin surface. Such capabilities will improve early diagnosis, detection, optimization of therapy, assessment of adequacy of resuscitation, and alteration in management plans for all of these critical conditions.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Beckman Laser Institute,University of California, Irvine
Irvine, California, United States
Trauma/Critical Care Units, UCI Medical Center
Orange, California, United States
Start Date
March 1, 2007
Primary Completion Date
April 1, 2011
Completion Date
April 1, 2011
Last Updated
November 1, 2022
93
ACTUAL participants
Diffuse optical spectroscopy
DEVICE
Lead Sponsor
University of California, Irvine
Collaborators
NCT04894734
NCT07480655
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions